Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch & Lomb's Crystalens approved by FDA

This article was originally published in Clinica

Executive Summary

Bausch & Lomb's Crystalens HD accommodating intraocular lens (IOL) has received premarket approval (PMA) from the US FDA. It is the fourth-generation Crystalens product – the first gained FDA clearance in November 2003. The Rochester, New York company hopes to launch the lens in Europe, Asia and Canada in early 2009. Bausch & Lomb agreed to buy Crystalens' developer eyeonics in January 2008 – before this it only offered monofocal IOLs. Crystalens is designed to correct presbyopia, the eye's inability to accommodate and focus on close objects, using the eye muscles to push the IOL back and forth. Crystalens HD has an enhanced optic which increases depth of focus to improve near vision without compromising intermediate or distance vision, Bausch & Lomb said.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041748

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel